- Home
- PRAX vs USPH Comparison
PRAX vs USPH Comparison
Compare PRAX & USPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRAX
- USPH
- Stock Information
- Founded
- PRAX 2015
- USPH 1990
- Country
- PRAX United States
- USPH United States
- Employees
- PRAX N/A
- USPH N/A
- Industry
- PRAX Biotechnology: Pharmaceutical Preparations
- USPH Medical/Nursing Services
- Sector
- PRAX Health Care
- USPH Health Care
- Exchange
- PRAX Nasdaq
- USPH Nasdaq
- Market Cap
- PRAX 950.8M
- USPH 1.1B
- IPO Year
- PRAX 2020
- USPH 1992
- Fundamental
- Price
- PRAX $47.08
- USPH $85.65
- Analyst Decision
- PRAX Strong Buy
- USPH Strong Buy
- Analyst Count
- PRAX 10
- USPH 4
- Target Price
- PRAX $102.00
- USPH $110.25
- AVG Volume (30 Days)
- PRAX 578.2K
- USPH 194.5K
- Earning Date
- PRAX 08-04-2025
- USPH 08-06-2025
- Dividend Yield
- PRAX N/A
- USPH 2.10%
- EPS Growth
- PRAX N/A
- USPH 116.39
- EPS
- PRAX N/A
- USPH 2.29
- Revenue
- PRAX $7,765,000.00
- USPH $722,201,000.00
- Revenue This Year
- PRAX N/A
- USPH $16.68
- Revenue Next Year
- PRAX $3,567.38
- USPH $6.05
- P/E Ratio
- PRAX N/A
- USPH $37.51
- Revenue Growth
- PRAX 338.45
- USPH 16.25
- 52 Week Low
- PRAX $26.70
- USPH $62.77
- 52 Week High
- PRAX $91.83
- USPH $101.20
- Technical
- Relative Strength Index (RSI)
- PRAX 42.83
- USPH 64.42
- Support Level
- PRAX $44.25
- USPH $69.80
- Resistance Level
- PRAX $49.97
- USPH $89.06
- Average True Range (ATR)
- PRAX 3.36
- USPH 3.03
- MACD
- PRAX -0.89
- USPH 1.38
- Stochastic Oscillator
- PRAX 18.84
- USPH 82.27
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
About USPH U.S. Physical Therapy Inc.
US Physical Therapy Inc through its subsidiaries operates outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries. The principal payment sources for the clinics' services are managed care programs, commercial health insurance, Medicare/Medicaid, workers' compensation insurance, and proceeds from personal injury cases. Its operating segment includes Physical therapy operations and Industrial injury prevention services. The company generates maximum revenue from the Physical therapy operations segment.